Sodium-glucose co-transporter 2 inhibitors: game changers when handled with care?
| Autor: | Zay Htet, Mahzuz Karim |
|---|---|
| Rok vydání: | 2024 |
| Předmět: |
medicine.medical_specialty
030209 endocrinology & metabolism Disease 030204 cardiovascular system & hematology Diabetes Complications 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Diabetes mellitus medicine Empagliflozin Humans In patient Dapagliflozin Intensive care medicine Sodium-Glucose Transporter 2 Inhibitors Canagliflozin business.industry General Medicine medicine.disease chemistry Diabetes Mellitus Type 2 Novel agents Cardiovascular Diseases Relative risk business medicine.drug |
| Zdroj: | Journal of the Royal Society of Medicine. 114(7) |
| ISSN: | 1758-1095 |
| Popis: | Recent years have seen a paradigm shift in the management of patients with diabetes mellitus. Rather than good glycaemic control being the sole primary aim, the therapeutic focus has broadened to consider potential additional cardiovascular and renal benefits. Sodium-glucose co-transporter 2 inhibitors, such as empagliflozin, canagliflozin and dapagliflozin, have gained increasing prominence, with evidence suggesting significant improvement in outcomes in patients with established cardiovascular and renal disease. Here, we discuss the benefits and relative risks of these novel agents and highlight important clinical issues of relevance to general physicians. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|